CL2022001357A1 - Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso - Google Patents
Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de usoInfo
- Publication number
- CL2022001357A1 CL2022001357A1 CL2022001357A CL2022001357A CL2022001357A1 CL 2022001357 A1 CL2022001357 A1 CL 2022001357A1 CL 2022001357 A CL2022001357 A CL 2022001357A CL 2022001357 A CL2022001357 A CL 2022001357A CL 2022001357 A1 CL2022001357 A1 CL 2022001357A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- delta
- methods
- heterocyclic compounds
- desaturase inhibitors
- Prior art date
Links
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 title abstract 3
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 title abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001357A1 true CL2022001357A1 (es) | 2023-03-10 |
Family
ID=73855555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001357A CL2022001357A1 (es) | 2019-11-25 | 2022-05-24 | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
| CL2023002486A CL2023002486A1 (es) | 2019-11-25 | 2023-08-22 | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002486A CL2023002486A1 (es) | 2019-11-25 | 2023-08-22 | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Country Status (21)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220510B2 (en) * | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| BR112022010054A2 (pt) | 2019-11-25 | 2022-08-16 | Amgen Inc | Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
| TW202434254A (zh) | 2022-11-23 | 2024-09-01 | 美商安進公司 | 選擇用於fads1調節劑治療的患者之方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| JP2641443B2 (ja) | 1986-04-07 | 1997-08-13 | クミアイ化学工業株式会社 | ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤 |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| IL130181A0 (en) | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
| KR20020045609A (ko) | 1999-10-15 | 2002-06-19 | 추후기재 | 고나도트로핀-분비 호르몬 수용체 길항제 및 이와 관련된방법 |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| AU2003238157A1 (en) | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| WO2006067401A1 (en) | 2004-12-24 | 2006-06-29 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| CA2612585A1 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
| EP1905238A4 (en) | 2005-07-18 | 2009-04-22 | Samsung Electronics Co Ltd | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| BRPI0614158A2 (pt) | 2005-07-27 | 2016-11-22 | Basf Ag | compostos, processo para reparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos |
| CN101228168A (zh) | 2005-07-27 | 2008-07-23 | 巴斯福股份公司 | 6-苯基吡唑并嘧啶-7-基胺杀真菌剂 |
| US20080200480A1 (en) | 2005-07-27 | 2008-08-21 | Basf Aktiengesellschaft | Fungicidal 6-Phenyltriazolopyrimidinylamines |
| TWI421078B (zh) | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
| BRPI0717134A2 (pt) | 2006-09-28 | 2013-10-15 | Novartis Ag | Derivados de pirazol [1,5-a] pirimidina e seu uso de terapêutico |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| BRPI0806347A2 (pt) | 2007-01-19 | 2011-09-06 | Basf Se | misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente |
| EP2131658A2 (en) | 2007-01-30 | 2009-12-16 | Basf Se | Method for improving plant health |
| WO2008116730A1 (de) | 2007-03-23 | 2008-10-02 | Basf Se | Wirkstoffkombinationen |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20090253704A1 (en) * | 2008-04-04 | 2009-10-08 | Dmitry Koltun | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US20100099561A1 (en) | 2008-10-15 | 2010-04-22 | E.I. Du Pont De Nemours And Company | Heterobicyclic alkylthio-bridged isoxazolines |
| UY32395A (es) * | 2009-01-27 | 2010-08-31 | Takeda Pharmaceutical | Compuesto con anillo fusionado y su uso |
| PL2448938T3 (pl) | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
| WO2011114148A1 (en) * | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US8952012B2 (en) | 2012-05-24 | 2015-02-10 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| CN105980386B (zh) | 2013-03-13 | 2021-08-13 | 基因泰克公司 | 吡唑并化合物及其用途 |
| WO2015035062A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Antiproliferative compounds |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| WO2015163339A1 (ja) | 2014-04-23 | 2015-10-29 | 田辺三菱製薬株式会社 | 新規二環性または三環性複素環化合物 |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2017091808A (ja) | 2015-11-10 | 2017-05-25 | 株式会社フジクラ | 酸化物超電導線材の製造方法及び超電導コイルの製造方法 |
| WO2017112678A1 (en) | 2015-12-21 | 2017-06-29 | Rima Mcleod | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| KR102411150B1 (ko) | 2016-08-31 | 2022-06-21 | 아지오스 파마슈티컬스 아이엔씨. | 세포 대사 과정의 억제제 |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN106749271B (zh) | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| US10738056B2 (en) | 2017-09-15 | 2020-08-11 | Aduro Biotech Inc. | Pyrazolopyrimidinone compounds and uses thereof |
| BR112022010054A2 (pt) | 2019-11-25 | 2022-08-16 | Amgen Inc | Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso |
-
2020
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en not_active Ceased
- 2020-11-24 PH PH1/2022/551282A patent/PH12022551282A1/en unknown
- 2020-11-24 CN CN202410291075.3A patent/CN118161500A/zh active Pending
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko active Pending
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-24 AU AU2020392087A patent/AU2020392087B2/en active Active
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active Active
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 IL IL293191A patent/IL293191B2/en unknown
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-25 TW TW112142068A patent/TWI867822B/zh active
- 2020-11-25 UY UY0001038971A patent/UY38971A/es unknown
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-24 SA SA522432710A patent/SA522432710B1/ar unknown
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US12448396B2/en active Active
-
2023
- 2023-03-27 JP JP2023049452A patent/JP7698676B2/ja active Active
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| ECSP11011198A (es) | Derivados de sulfonamida | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| CL2019003747A1 (es) | Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock. | |
| CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
| EA201100447A1 (ru) | Органические соединения | |
| AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
| AR056049A1 (es) | 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm | |
| UY38972A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |